Phaseline

Targets › CALCR

CALCR (Calcitonin receptor): drug programs, companies and trials

6 programs from 5 companies in 31 trials: 14 Phase 3, 11 Phase 1, 5 Phase 2, 1 Phase 4; Metabolic and endocrine, Cardiovascular, Other; next expected readout Nov 2026.

G protein-coupled receptor activated by ligand peptides amylin (IAPP), calcitonin (CT/CALCA) and calcitonin gene-related peptide type 1 (CGRP1/CALCA). CALCR interacts with receptor-activity-modifying proteins RAMP1, 2 and 3 to form receptor complexes AMYR1, 2 and 3, respectively. (UniProt, P30988)

Open in Phaseline: the race on CALCR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Joseph SferraCalcitonin
Calcitonin receptor agonist - lowers serum calcium levels
CALCRPhase 4Primary HyperparathyroidismDec 2026
Novo NordiskCagrilintide B
Dual GLP-1/glucagon receptor agonist
GLP1R, GCG, CALCRPhase 3Obesity; Overweight; Cardiovascular Disease; Diabetes Mellitus, Type 2Jan 2027
Novo NordiskCagriSema
Amylin and GLP-1 receptor agonist combination
GLP1R, CALCRPhase 3Obesity; Diabetes Mellitus, Type 2; OverweightJun 2027
KeyBioscienceKBP-336
Dual Amylin and Calcitonin Receptor agonist
CALCR, ABCAMPhase 2Osteoarthritis in the KneeNov 2026
AbbVieABBV-295
amylin analog
CALCRPhase 2Obesity; Healthy VolunteerJan 2027
Eli LillyMacupatide (LY3532226)
Amylin receptor agonist
CALCRPhase 2Obesity; OverweightMar 2027

Conditions

Obesity (18) Overweight (7) Diabetes Mellitus, Type 2 (2) Cardiovascular Disease (1) Healthy Volunteer (1) Osteoarthritis in the Knee (1) Primary Hyperparathyroidism (1)

Modalities

protein or peptide (3), small molecule (3)

Companies

Novo Nordisk (2) AbbVie (1) KeyBioscience (1) Joseph Sferra (1) Eli Lilly (1)

Related targets

GLP1R (2) GCG (1) ABCAM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.